This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, J. C. L.
Right arrow Articles by Parmacek, M. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, J. C. L.
Right arrow Articles by Parmacek, M. S.

 Previous Article  |  Next Article 

Molecular and Cellular Biology, February 2001, p. 1336-1344, Vol. 21, No. 4
0270-7306/01/$04.00+0   DOI: 10.1128/MCB.2001.21.4.1336-1344.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Analysis of SM22alpha -Deficient Mice Reveals Unanticipated Insights into Smooth Muscle Cell Differentiation and Function

Janet C. L. Zhang,1 Steven Kim,2 Brian P. Helmke,3 William W. Yu,1 Kevin L. Du,1 Min Min Lu,1 Mark Strobeck,1 Qian-Chun Yu,4 and Michael S. Parmacek1,*

Departments of Medicine,1 Bioengineering,3 and Cell and Molecular Engineering,4 University of Pennsylvania, Philadelphia, Pennsylvania 19104, and Department of Medicine, University of Chicago, Chicago, Illinois 606372

Received 17 October 2000/Accepted 7 November 2000


    ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

SM22alpha is a 22-kDa smooth muscle cell (SMC) lineage-restricted protein that physically associates with cytoskeletal actin filament bundles in contractile SMCs. To examine the function of SM22alpha , gene targeting was used to generate SM22alpha -deficient (SM22-/-LacZ) mice. The gene targeting strategy employed resulted in insertion of the bacterial lacZ reporter gene at the SM22alpha initiation codon, permitting precise analysis of the temporal and spatial pattern of SM22alpha transcriptional activation in the developing mouse. Northern and Western blot analyses confirmed that the gene targeting strategy resulted in a null mutation. Histological analysis of SM22+/-LacZ embryos revealed detectable beta -galactosidase activity in the unturned embryonic day 8.0 embryo in the layer of cells surrounding the paired dorsal aortae concomitant with its expression in the primitive heart tube, cephalic mesenchyme, and yolk sac vasculature. Subsequently, during postnatal development, beta -galactosidase activity was observed exclusively in arterial, venous, and visceral SMCs. SM22alpha -deficient mice are viable and fertile. Their blood pressure and heart rate do not differ significantly from their control SM22alpha +/- and SM22alpha +/+ littermates. The vasculature and SMC-containing tissues of SM22alpha -deficient mice develop normally and appear to be histologically and ultrastructurally similar to those of their control littermates. Taken together, these data demonstrate that SM22alpha is not required for basal homeostatic functions mediated by vascular and visceral SMCs in the developing mouse. These data also suggest that signaling pathways that regulate SMC specification and differentiation from local mesenchyme are activated earlier in the angiogenic program than previously recognized.


    INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Smooth muscle cells (SMCs) subserve a variety of functions in higher vertebrates, including the regulation of arterial tone, the control of airway resistance, and the modulation of gastrointestinal and genitourinary tract contractility and basal tone. Despite the myriad of functions mediated by SMCs, relatively little is understood about the developmental programs that regulate SMC specification and differentiation. This is due, in part, to the complex embryological origins of the SMC lineage(s) and the lack of definitive SMC markers (27, 28). In contrast to striated muscle cells which terminally differentiate, SMCs retain their capacity to proliferate and modulate their phenotype during postnatal development (27, 34, 36, 37). This characteristic presumably evolved to facilitate reparative processes such as wound healing. However, it has also been implicated in the pathophysiology of a number of disease processes, including hypertension, restenosis following angioplasty, posttransplant arteriopathy, and asthma (13, 25, 32, 34).

Cytoskeletal dynamics and organization play an important role in regulating SMC morphology and phenotype (for a review, see reference 41). The SMC cytoskeleton is composed of actin filaments, as well as intermediate filaments and their associated proteins. The insoluble network of intermediate filaments has been implicated in the maintenance of SMC shape (42). The intermediate filaments colocalize with a subpopulation of F-actin filament bundles that is distinct from the contractile apparatus (26). The cytoskeletal actin filaments and smooth muscle actin converge upon alpha -actinin-containing dense bodies that serve as a possible coupling point between the SMC contractile apparatus and the cytoskeleton (26). Cytoskeletal actin filaments are anchored within focal adhesions which form rib-like arrays over the entire SMC surface (40). The geometric organization of these arrays assures that contractile tension is distributed uniformly over the SMCs to the extracellular matrix.

SM22alpha is a 22-kDa cytoskeletal protein that is expressed abundantly and exclusively in visceral and vascular SMCs during postnatal development. SM22alpha has been variably designated SM22alpha (17, 37), transgelin (16), WS3-10 (45), and p27 (1). SM22alpha mRNA has been detected in the dorsal aorta of the mouse embryo as early as embryonic day 9.5 (E9.5) (18). Like most other markers of the SMC lineage, SM22alpha is also expressed in embryonic cardiac and skeletal muscle through mid-gestation (6, 17, 18, 37). SM22alpha is downregulated in concert with other SMC-restricted myofibrillar proteins in late-passage primary aortic SMCs and in neointimal SMCs that arise in response to arterial injury (35, 36). In human atherosclerotic lesions, SM22alpha is downregulated within neointimal SMCs but is expressed in SMCs that form the fibrous caps of complicated atherosclerotic lesions (35, 36). Our group, and others, reported that the mouse SM22alpha promoter restricts transgene expression to arterial SMCs, suggesting that distinct transcriptional programs may distinguish previously unrecognized SMC sublineages (14, 19, 22, 43). The activity of the mouse SM22alpha promoter is critically dependent upon two CArG box-containing elements that bind the MADS box transcription factor SRF (14, 19, 22, 43).

Despite the fact that SM22alpha is expressed abundantly in SMCs and has been localized within the cytoskeletal apparatus, relatively little is understood about its function. SM22alpha shares high-level amino acid sequence identity with several other proteins, including the thin filament SMC-restricted myofibrillar regulatory protein calponin (33, 44), the Caenorhabditis elegans body wall muscle protein Unc-87 (8), the Drosophila muscle protein Mp20 (2), and the neuronal-restricted protein NP25 (31). Mutation of the unc-87 and mp20 genes results in paralysis of the C. elegans body wall and of the Drosophila flight muscle, respectively (2, 8). SM22alpha colocalizes to actin filament bundles and stress fibers (41). Purified SM22alpha protein binds directly to actin filaments at a ratio of 1:6 actin monomers (38, 39). These data suggest that SM22alpha may serve to organize the spatial relationships of actin filaments in SMCs (38, 39, 41). In this regard, it is also noteworthy that SM22alpha gene expression is downregulated when vascular SMCs assume a synthetic phenotype and by cellular transformation processes that involve major cytoskeletal rearrangements (35, 37). Taken together, these data suggest that SM22alpha may play a role in organization of the cytoskeleton and directly, or indirectly, regulate SMC morphology or other processes involving the cytoskeleton.

In the studies described here, gene targeting was used to define precisely the spatial and temporal patterns of SM22alpha transcriptional activation during vascular development and to examine the function of the SM22alpha protein in SMCs. Surprisingly, in E8.0 SM22+/-LacZ embryos beta -galactosidase activity was observed in the dorsal aorta. This is 24 to 36 h prior to the documented expression of genes encoding vascular SMC markers in the embryonic mouse. During postnatal development, SM22alpha gene was activated exclusively in visceral and vascular SMCs. SM22alpha -deficient embryos (SM22-/-) are viable and fertile and develop normally. SMC-containing tissues from SM22alpha -deficient mice are histologically indistinguishable from the tissues of their control littermates, and only subtle defects in the arrangement of actin filaments are observed in SM22alpha -deficient SMCs. These data demonstrate that SM22alpha is not required for the normal development of the mouse embryo and basal homeostatic functions mediated by SMCs. In addition, these data demonstrate that the devleopmental program leading to vascular stabilization and patterning during embryonic development is initiated earlier than was suggested by previous studies.


    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Molecular cloning and generation of SM22alpha mutant embryonic stem (ES) cells and mice. A genomic clone including the 5' end of the murine SM22alpha gene was isolated from an SV129 mouse library (43). The targeting vector was generated in the pPNT plasmid (46), which contains the PGK-neo-poly(A) and PGK-tk-poly(A) cassettes for positive and negative selection, respectively. As schematically represented in Fig. 1A, the pPNTSM22.LacZ targeting vector contains a genomic subfragment that includes approximately 5-kb of the SM22alpha 5' flanking sequence, exon 1, intron 1, and exon 2 sequence through the initiation codon (denoted as ATG). This was cloned in frame to the bacterial lacZ reporter gene (denoted as LacZ), which in turn was subcloned into NotI/XhoI-digested pPNT. The targeting vector also includes the 2.6-kb BamHI/NcoI SM22alpha genomic subfragment that spans exon 4 through intron 5 sequences subcloned into the EcoRI site of pPNT. In pPNTSM22.LacZ, sequences 3' of the initiation codon of exon 2 are replaced by the lacZ reporter gene and the PGK-neo cassette.


View larger version (32K):
[in this window]
[in a new window]
 
FIG. 1.   Targeted disruption and insertion of lacZ gene into the SM22alpha gene. (A) Schematic representation of the SM22alpha targeting strategy. (Top) Partial restriction endonuclease map of the murine SM22alpha genomic locus showing BamHI (B) and EcoRI (R1) sites. Exons are shown in black. (Middle) SM22alpha targeting vector containing the neomycin resistance (neo) and herpes simplex virus thymidine kinase (tk) genes under the control of the PGK promoter. (Bottom) Structure of the targeted mutant SM22alpha allele and location of the probe used in Southern blot analyses. (B) Southern blot analysis of DNA prepared from the offspring of SM22+/-LacZ × SM22+/-LacZ mating. DNA was digested with EcoRI and hybridized to the radiolabeled SM22alpha genomic probe shown in Fig. 1A. The positions of the wild-type (14-kb) and targeted (10-kb) allele are indicated with arrows at left. (C) (Top) Northern blot analysis of SM22alpha gene expression in aortic RNA harvested from wild-type (+/+), heterozygous (+/-), and homozygous-null (-/-) mice. (Bottom) Loading and integrity of RNA was assessed by ethidium bromide staining of the 28S RNA in the gel prior to membrane transfer. (D) Western blot analysis of protein lysates prepared from the aorta of wild-type (+/+), heterozygous (+/-), and homozygous-null (-/-) mice. Protein was fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to Immobilon-P membrane, incubated with rabbit alpha -mouse SM22alpha polyclonal antiserum, and visualized with goat anti-mouse horseradish peroxidase-coupled secondary antibody. The 22-kDa marker is shown to the right.

The SM22alpha targeting construct was linearized with NotI and electroporated into RW ES cells as described previously (24). After 24 h, neomycin-resistant transfectants were selected in 250 µg of G418 per ml and 1 µM gancyclovir for 8 to 10 days. DNA from resistant ES cell clones was analyzed by Southern blot analysis after EcoRI digestion with a radiolabeled probe derived from genomic sequences located 3' of the targeting vector (see Fig. 1A). To generate SM22alpha -deficient mice, ES cells from two independently derived SM22+/-LacZ clones were microinjected into C57BL/6 donor blastocysts that were implanted into pseudopregnant CD1 females (3, 12). The resulting male chimeras were mated with C57BL/6 females, and agouti offspring were genotyped by Southern blot analysis as described previously (24). SM22+/-LacZ mice were then outbred with C57BL/6 and CD1 mice to generate heterozygous SM22-/-LacZ mice that were interbred for phenotype analysis. All animal experimentation was performed according to National Institutes of Health guidelines in the University of Pennsylvania Animal Care Facility.

Preparation of SM22alpha polyclonal antiserum. The pGEX4TSM22alpha expression plasmid encoding the glutathione S-transferase (GST)-mouse SM22alpha (amino acids 1 to 201) fusion protein was transformed into bacteria, and GST-SM22alpha fusion protein was induced and purified from bacterial extracts as described previously (23). Rabbits were immunized with the purified GST-SM22alpha fusion protein according to the standard protocol of Cocalico Biologicals, Inc. (Reamstown, Pa.). Preimmune immunoglobulin G (IgG) and anti-SM22alpha polyclonal IgG (no. 1387-4) were isolated from the serum by GST-SM22alpha affinity chromatography and protein A-Sepharose chromatography.

Northern and Western blot analyses. RNA was isolated from tissues of wild-type, heterozygous SM22+/-LacZ, and homozygous SM22-/-LacZ mice as described elsewhere (24). Northern blot analyses were performed using 10 µg of RNA/sample, and the radiolabeled 754-bp (bp 29 to 811) mouse SM22alpha cDNA probe as described previously (29). Western blot analyses were performed as described earlier using the affinity-purified rabbit polyclonal alpha -SM22alpha antiserum and control rabbit preimmune IgG (17).

Cardiovascular physiological assessment. The systolic blood pressure (SBP) and heart rate (HR) of conscious wild-type, heterozygous (SM22+/-LacZ), and homozygous-null (SM22-/-LacZ) adult male mice were compared using a mouse physiological recording system according to the manufacturer's instructions (Visitech System, Apex, N.C.). Each measurement was performed in triplicate and was repeated the following day to ensure reproducibility. To assess cardiac function in wild-type, heterozygous (SM22+/-LacZ), and homozygous-null (SM22-/-LacZ) adult male mice, echocardiography was performed using an S12 transducer (5 to 12 MHz) and a HP5500 Sonos system as described earlier (7). M-mode tracings were made at the level of the papillary muscle in the left ventricular (LV) short-axis view. The heart rate was determined from the M-mode and pulsed-Doppler tracings of the peak aortic flow velocity in the ascending aorta. On-line measurement of LV dimensions was made using a Tom Tec Imaging System. End-systolic and diastolic dimensions were determined by plainimetry. The percent left ventricular fractional shortening was calculated using a standard formula: [(LVEDd - LVESd)/LVEDd] × 100. The percent ejection fraction was estimated from the fractional area change (FAC) in the LV short-axis view as follows: FAC = [(LVEDa - LVESa)/LVEDa] × 100. Color flow mapping and pulsed Doppler wave forms were obtained across the pulmonary artery to evaluate patent ductus arteriosus. The statistical significance was calculated by analysis of variance ANOVA and by two-tailed unpaired Student t test (a P value of <0.05 was considered significant).

Cell biology, histology, and ultrastructural analyses. Tissues from adult wild-type and SM22-/-LacZ mice were fixed, embedded in paraffin, sectioned, and stained with hematoxylin and eosin as described previously (24). Embryos and tissue sections from adult mice were fixed and stained for beta -galactosidase activity and counterstained with hematoxylin and eosin as described previously (5). A7r5 SMCs were stably transfected with an expression plasmid encoding Ds-RED epitope-tagged mouse SM22alpha as described previously (15). Three-dimensional (3-D) fluorescence images of A7r5 cells and primary SMCs were acquired using a Delta Vision microscopy system (Applied Precision, Issaquah, Wash.) equipped with an appropriate barrier filter set (Chroma, Battleboro, Vt.) for Ds-Red or rhodamine (lambda ex = 555 nm, lambda em = 617 nm). Spatial and temporal normalization of the illumination intensity allowed quantitative analysis of the fluorescence intensity (11). A constrained iterative deconvolution algorithm (11) using an experimentally measured point spread function was applied to 3-D arrays of optical sections to yield a high-resolution spatial distribution of fluorescence intensity that accurately represented the 3-D cytoskeletal structure (9). Image restoration and volume projections were computed using SoftWoRx software (Applied Precision). For electron microscopy, the aorta and bladder from wild-type and SM22-/-LacZ mice were fixed in 2.5% glutaraldehyde and 2% paraformaldehyde and then postfixed with 2% aqueous osmium tetroxide as described previously (4). The samples were washed and dehydrated with ethanol and embedded in LX-112 medium that was polymerized at 70°C for 48 h. Ultrathin sections (80 nm) were cut with a diamond knife and stained with uranyl acetate. Immunogold labeling of tissue sections was performed as described previously (4). Samples were fixed with 2% paraformaldehyde and 0.05% glutaraldehyde in phosphate-buffered saline for 1 h, treated with 10 mM NH4Cl for 30 min, dehydrated at -20°C, and embedded in Lowicryl K4M medium. The samples were polymerized with UV light (365 nm), and ultrathin sections (90 nm) were cut, mounted on Formvar-coated nickel grids, blocked with 1% bovine serum albumin and 2% goat serum, and incubated with affinity-purified anti-SM22alpha polyclonal antiserum or control rabbit IgG at a 1:100 dilution. The sections were then incubated with 15-nm gold-conjugated anti-rabbit IgG and stained with uranyl acetate, and the images were visualized with a Philips CM100 electron microscope at 60 kV.


    RESULTS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Targeted disruption of the SM22alpha gene and insertion of lacZ in ES cells and mice. To produce a targeted disruption and insertion of the lacZ reporter gene in the mouse SM22alpha locus, a targeting vector was constructed in which the lacZ gene was inserted in-frame at the SM22alpha initiation codon (ATG), and the remainder of exon 2, intron 2, exon 3, and part of intron 3 were replaced with the phosphoglycerokinase-neomycin (neo) cassette (Fig. 1A). The linearized targeting vector was electroporated into RW ES cells. Of 89 G418- and gancyclovir-resistant ES cell colonies screened, 6 were shown to be homologous recombinants by Southern blot analyses. Each of these SM22+/-LacZ clones contained a single site of integration of the vector in the host genome as determined by Southern blot analyses performed with a neo probe (data not shown).

Two independently derived SM22+/-LacZ ES cell lines were used to generate chimeric mice, and these mice were crossed to C57BL/6 mice to transmit the targeted allele through the germ line as determined by Southern blot analysis (Fig. 1B). Heterozygous SM22+/-LacZ mice were phenotypically normal and fertile. These mice were outbred to the BL/6 and CD1 background to produce heterozygotes that were intercrossed to generate homozygous SM22-/-LacZ mice. To confirm that a null mutation was created with this targeting strategy, Northern blot analyses were performed on RNA isolated from SMC-containing tissues (aorta and uterus) harvested from wild-type (SM22+/+), heterozygous (SM22+/-LacZ), and homozygous (SM22-/-LacZ) null mice. As anticipated, a 1.3-kb transcript corresponding to the expected size of SM22alpha mRNA was observed in samples of RNA prepared from the aorta (Fig. 1C, lanes 1 and 2) and uterus (data not shown) of wild-type and heterozygous mice. In contrast, hybridization of the radiolabeled SM22alpha cDNA probe to RNA samples prepared from the tissues of SM22-/-LacZ mice was not detected (Fig. 1C, lane 3). Western blot analyses performed with SM22alpha -specific polyclonal antiserum and tissue lysates prepared from the aorta of wild-type (SM22+/+), heterozygous (SM22+/-LacZ), and homozygous (SM22-/-LacZ) null mice revealed the expected 22-kDa band (Fig. 1D, lanes 1 and 2). In addition, a 20-kDa signal was reproducibly observed in lysates prepared from the aorta of wild-type (SM22+/+) and heterozygous (SM22+/-LacZ) mice. In contrast, no hybridization signal was detected in tissue lysates prepared from the aorta (Fig. 1D, lane 3) and uterus (data not shown) of homozygous SM22-/-LacZ null mice. Taken together, these data demonstrate that the gene targeting strategy utilized generated a null mutation in the gene encoding SM22alpha .

Transcriptional activation of the SM22alpha gene in the embryonic and adult mouse. The gene targeting strategy effectively knocked in the bacterial lacZ reporter gene under the transcriptional control of the endogenous SM22alpha promoter, as well as other unidentified elements flanking and within the SM22alpha gene. To determine when and where in the postgastrulation embryo the SM22alpha gene is transcribed, E8.0 SM22+/-LacZ embryos were harvested from staged matings of SM22+/-LacZ × SM22+/-LacZ mice and stained for beta -galactosidase activity. At E8.0, the process of "embryonic turning" is initiated, the heart consists of common atrial and ventricular chambers, and the unfused dorsal aortae are easily recognizable. In the E8.0 SM22+/-LacZ embryo, beta -galactosidase activity (blue staining) was obvious within the head, heart, cardiac outflow tract, dorsal aorta, and yolk sac membranes (Fig. 2A). Sections obtained through the headfold revealed that lacZ-positive cells were restricted to the cephalic mesenchyme (Fig. 2B). No staining was observed within the neuroepithelium or surface ectoderm (Fig. 2B). Sections through the superior thoracic cavity revealed blue-stained pericardial and myocardial cells. In contrast, the single layer of endocardial cells did not express beta -galactosidase (Fig. 2C). In addition, blue-stained cells were reproducibly observed surrounding the paired dorsal aorta (Fig. 2C and D, A.). Of note, this is 24 to 36 h prior to the reported expression of genes encoding SMC markers in the mouse embryo (27). Finally, scattered blue stained cells were observed within the paraxial mesoderm (Fig. 2D), which gives rise to the somites and in the notochord (Fig. 2C).


View larger version (66K):
[in this window]
[in a new window]
 
FIG. 2.   The SM22alpha gene is activated in the dorsal aorta of the E8.0 embryo. E8.0 SM22+/-LacZ embryos harvested from staged matings of SM22+/-LacZ × SM22+/-LacZ mice genotyped by Southern blot analyses and stained for beta -galactosidase activity as described in Materials and Methods. (A) Whole-mount beta -galactosidase activity in an E8.0 SM22+/-LacZ embryo. beta -Galactosidase activity (blue staining) is observed in the embryonic heart, aorta, cephalic mesenchyme (CM), and yolk sac. The planes of the sections shown in panels B, C, and D are indicated by white lines. (B) Cross-section through the head of an E8.0 SM22+/-LacZ embryo showing beta -galactosidase activity restricted to cells within the cephalic mesenchyme (CM). Staining was not observed in the surface ectoderm (ECT) or neuroepithelium (NE). (C) Cross-section through the thoracic cavity of an E8.0 SM22+/-LacZ embryo demonstrating beta -galactosidase activity in the myocardium (Myo), pericardium (P), aorta (Ao), and notochord (NC). (D) High-power view of a section through the thoracic cavity of an E8.0 SM22+/-LacZ embryo demonstrating beta -galactosidase activity in cells surrounding the paired dorsal aorta (Ao). In addition, faint blue staining is observed in scattered cells within the paraxial mesoderm (PM), which gives rise to the somites.

Histochemical analyses of adult SM22+/-LacZ mice revealed, as anticipated, beta -galactosidase activity (blue-stained cells) in the tunica media of the major and branch arteries, including the aorta (Fig. 3A) and the diaphragmatic arteries (Fig. 3B). Blue staining was also observed within arterioles (Fig. 3C, arrow) located within the kidneys and other tissues. This pattern of expression recapitulated the pattern of lacZ expression observed in transgenic mice harboring the mouse SM22alpha promoter (14, 19, 22). However, in contrast to the pattern of beta -galactosidase activity observed in SM22alpha promoter-driven transgenic mice, the coronary arteries, which have a unique embryological derivation, also stained dark blue (Fig. 3D). Similarly, venous (Fig. 3E) and visceral SMCs, including those in the bladder (Fig. 3F), intestine (Fig. 3G), and stomach (Fig. 3H), as well as the bronchial SMCs (Fig. 3I, Br), were beta -galactosidase positive in SM22+/-LacZ mice. Taken together, these data demonstrate that the SM22alpha gene is activated at least 24 to 36 h prior to the documented expression of SMC markers in presumptive vascular SMCs. In addition, these data demonstrate that the knock-in of the lacZ gene into the endogenous SM22alpha locus restricts beta -galactosidase gene expression to vascular and visceral SMCs during postnatal development in the mouse.


View larger version (79K):
[in this window]
[in a new window]
 
FIG. 3.   beta -Galactosidase activity in SM22+/-LacZ mice is restricted to vascular and visceral SMCs. Tissues were harvested from SM22+/-LacZ mice, fixed, stained with X-Gal (5-bromo-4-chloro-3-indolyl-beta -D-galactopyranoside) and counterstained with hematoxylin and eosin as described in Materials and Methods. beta -Galactosidase activity (blue staining) was observed in the tunica media of the aorta (A), the diaphragmatic arteries (B), the tunica media of resistance arterioles (arrow) within the kidneys (C), the right coronary artery (D), veins (E), the muscular wall of the bladder (F), the lamina propria of the small intestine (G), and the muscular wall of the stomach (H), as well as in bronchial SMCs (Br) surrounding the bronchial epithelium (EP) (I).

Analyses of SM22alpha -deficient mice. As shown in Table 1, among 127 live-born offspring from SM22+/-LacZ × SM22+/-LacZ matings, 32 wild-type (SM22+/+), 55 heterozygous (SM22+/-LacZ), and 40 homozygous (SM22-/-LacZ)-null mice were generated. This ratio does not differ significantly from the expected Mendelian distribution, demonstrating that SM22alpha -deficient mice survive to birth. The weight of age-matched littermates also did not differ significantly between wild-type, heterozygous, and SM22alpha -null mice. In addition, the SBP and HR of conscious adult wild-type (SM22+/+) and SM22alpha -deficient mice (SM22-/-LacZ) did not differ significantly (Table 1). Taken together, these data suggest that SM22alpha is not required for basal homeostatic functions mediated by SMCs in the developing mouse.

                              
View this table:
[in this window]
[in a new window]
 
TABLE 1.   Physiological parameters in wild-type and SM22alpha -deficient mice

To determine whether SM22alpha was required for the normal development of the mouse, tissues obtained from SM22alpha -deficient mice and their control littermates were compared (Fig. 4). As shown in Fig. 2, the SM22alpha gene is expressed at high levels in the embryonic heart. However, hearts obtained from SM22alpha -deficient mice were indistinguishable from their control littermates (compare Fig. 4A and B). Moreover, the results of an echocardiographic comparison of chamber size, ventricular wall thickness, and indices of contractile function, including left ventricular fractional shortening and ejection fraction, did not differ significantly (data not shown). Similarly, the arteries and veins of wild-type and SM22alpha -deficient adult mice were virtually indistinguishable, including quantitative morphometric analyses of the arterial intima to media ratios (compare Fig. 4C and D). In addition, visceral organs obtained from wild-type and SM22alpha -deficient mice, including the small intestine (compare Fig. 4E and F) and uterus (compare Fig. 4G and H), developed normally and were histologically indistinguishable.


View larger version (111K):
[in this window]
[in a new window]
 
FIG. 4.   SMC-containing tissues develop normally in SM22alpha -deficient mice. Tissues harvested from wild-type (wt) and SM22alpha -deficient (-/-) mice were fixed and stained with hematoxylin and eosin as described in Materials and Methods. (A and B) Comparison of hearts from wild-type (A) and -/- (B) mice demonstrating normal left ventricular (LV) and right ventricular (RV) chamber dimensions and morphology. (C and D) Comparison of the aorta harvested from a wild-type (C) and -/- (D) adult mouse demonstrating normal tunica intima (End), tunica media (M), and adventitia (AD). (E and F) Comparison of small intestine harvested from wild-type (E) and -/- (F) mice demonstrating intact lamina propria and intestinal epithelium (EP). (G and H) Comparison of uterus harvested from wild-type (G) and -/- (H) mice demonstrating normal SMC arrangement within the muscular layers (SMCs) of the uterus.

Ultrastructural analyses of SM22alpha -deficient SMCs. SM22alpha colocalizes to the cytoskeleton of SMCs (38, 39, 41). Therefore, it was of interest to define the subcellular localization of SM22alpha in SMCs and to determine whether SM22alpha -deficient SMCs exhibited alterations in cytoskeletal architecture. A 3-D reconstruction of A7r5 SMCs that stably expressed a Ds-Red-tagged SM22alpha protein revealed localization to the F-actin filament bundles (Fig. 5A). This pattern of expression was identical to that observed when these cells were stained with the actin-binding protein phalloidin (data not shown). Immunogold localization of SM22alpha protein performed using affinity-purified SM22alpha polyclonal antiserum revealed gold particles (black dots) localizing to longitudinally oriented actin filaments in the cytoplasm and patches at the cell periphery (Fig. 5B). In addition, gold-labeled SM22alpha protein was also observed on the surface of some myosin bundles (dark patches in Fig. 5B). Signal (black dots in Fig. 5B) was not detected in the extracellular space, fibroblasts, or endothelial cells (data not shown). Hybridization to actin filaments (or other subcellular structures and organelles) was not observed in control experiments performed by substituting rabbit IgG for affinity-purified rabbit anti-SM22alpha IgG. These data confirm that SM22alpha is a component of the SMC cytoskeleton that colocalizes localizes with filamentous actin.


View larger version (129K):
[in this window]
[in a new window]
 
FIG. 5.   Cytoskeletal organization of wild-type and SM22alpha -deficient SMCs. (A) Cellular localization of Ds-Red-tagged SM22alpha in A7r5 SMCs. 3-D fluorescence images of A7r5 cells that stably express Ds-RED epitope-tagged SM22alpha were acquired using a Delta Vision micrscopy system, and image restoration and volume projections were computed as described in Materials and Methods. SM22alpha protein (white lines) localized to actin filament bundles. (B) Subcellular distribution of SM22alpha in the intact mouse aorta. Ultrathin sections of mouse aorta were incubated with affinity-purified anti-SM22alpha polyclonal antiserum. The sections were then incubated with gold-conjugated anti-rabbit IgG and stained with uranyl acetate. The anti-SM22alpha antibody (black dots) hybridized to longitudinally oriented actin filaments located throughout the cytoplasm and at the cell periphery. (C and D) 3-D fluorescence images of primary mouse aortic SMCs isolated from a wild-type (C) and SM22alpha -deficient (D) mouse stained with rhodamine-labeled phalloidin. Actin filament bundles (white lines) form well-organized rib-like arrays in the SM22alpha -deficient mouse (-/-, D) and its control littermate (+/+, C). No significant differences in fluorescence intensity in staining were detected. Bar, 1 µm. (E and F) Ultrastructural comparison of SMCs in the intact bladder of wild-type (E) and SM22alpha -deficient (F) mice. The bladder was fixed, embedded, sectioned, and stained, and images were generated with a Philips CM-100 electron microscope as described in Materials and Methods. Compared to the SMCs in the wild-type bladder which demonstrate obvious well-spaced, longitudinally oriented actin filaments (+/+, F), the cytoplasm of SM22alpha -deficient SMCs appears to be homogeneous, reflecting differences in spacing of the actin filaments. This resulted in more-condensed-appearing cytoplasmic bundles (arrows). Magnification, ×104,125.

To determine whether SM22alpha -deficient SMCs display normal cytoskeletal organization, 3-D fluorescence images of primary aortic SMCs isolated from wild-type (SM22+/+) and SM22alpha -null (SM22-/-LacZ) mice were stained with rhodamine-conjugated phalloidin and then compared after deconvolution and image restoration. In both wild-type aortic SMCs (Fig. 5C) and SM22alpha -deficient SMCs (Fig. 5D), rib-like arrays of actin filament bundles were observed throughout the cytoplasm. Consistent with this observation, no significant differences were observed in the pattern of alpha -actinin, desmin, and beta -tubulin expression in aortic SMCs isolated from wild-type and SM22alpha -deficient mice (data not shown). Electron microscopic examination of SM22alpha -deficient SMCs within the tunica media of the aorta and the bladder revealed no obvious ultrastructural abnormalities (compare Fig. 5E and F). There were no signs of cell death, degeneration, or fragmentation in SM22alpha -deficient SMCs. SM22alpha -null SMCs demonstrated a centrally located nucleus, normal organelle content and structure, and an intact plasma membrane with marginal vesicles (data not shown). Many of the wild-type and SM22-/-LacZ SMCs showed indentation of the nuclear envelope caused by muscular contraction. All of the SM22alpha -deficient SMCs contained abundant cytoskeletal filaments in the form of nonbanding bundles that ran parallel to the longitudinal axis of the cells. In addition, dense bodies were observed within the cytoplasm and at the cell periphery. The only discernible difference observed between wild-type (+/+) and SM22alpha -deficient (-/-) SMCs was the more homogeneous appearance of the cytoplasm in SM22alpha -deficient SMCs that reflects a difference in the spacing of myofilaments. This resulted in condensed-appearing ctyoplasmic bundles in SM22alpha -deficient SMCs within the bladder (arrow in Fig. 5F) and aorta (data not shown). Taken together, these data demonstrate that targeted mutation in the gene encoding SM22alpha does not result in a gross disruption of cytoskeletal organization.


    DISCUSSION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

SM22alpha is a cytoskeletal protein that is expressed abundantly and exclusively in SMCs during postnatal development. In the studies described here, gene targeting was used to generate mice harboring a null mutation in the gene encoding SM22alpha and insertion of the lacZ gene into the SM22alpha locus. Analyses of heterozyogous SM22+/-LacZ embryos revealed that the SM22alpha gene is transcribed in the dorsal aorta at E8.0, serving to identify this as the earliest recognized event in the developmental program leading to differentiation of vascular SMCs from undifferentiated mesenchyme. During postnatal development, beta -galactosidase activity was restricted to visceral and vascular SMCs. This pattern of distribution recapitulates the expression pattern of the endogenous SM22alpha gene but differs significantly from SM22alpha promoter-driven transgenic mice (14, 19, 22, 43). SM22alpha -deficient mice are viable and fertile and exhibit no obvious phenotypic abnormalities. SMC-containing tissues, including the vasculature, heart, uterus, stomach, intestine, and bladder, all developed normally. Consistent with these findings, the cytoskeletal organization of SM22alpha -deficient and wild-type vascular and visceral SMCs is virtually indistinguishable.

Our group and others have reported that the SM22alpha promoter restricts expression of a lacZ reporter gene to arterial SMCs in transgenic mice (14, 19, 22, 43). In SM22alpha promoter-driven transgenic mice, beta -galactosidase activity is not observed in venous, coronary arterial, or visceral SMCs despite the fact that the endogenous SM22alpha gene is expressed in these cells. This led to the hypothesis that distinct transcriptional programs distinguish tissue-restricted subsets of SMCs or SMC sublineages. This hypothesis was supported by the finding that the smooth muscle alpha -actin promoter and intragenic enhancer (20), the smooth muscle myosin heavy-chain promoter and intragenic enhancer (21), the telokin promoter (10), and the gamma -enteric actin promoter (30) restrict transgene expression to unique tissue-restricted subsets of SMCs in transgenic mice. It is noteworthy that each of these transcriptional regulatory elements also contains a functionally important CArG box that binds directly to the MADS box transcription factor SRF. The observed beta -galactosidase activity in visceral and vascular SMCs of SM22+/-LacZ mice is consistent with this model and leads us to predict that additional, as-yet-unidentified, transcriptional regulatory elements required for expression in venous, coronary arterial, and visceral SMCs exist and are located in distant regions flanking the SM22alpha gene. Identification and characterization of these regulatory elements should provide fundamental insights into the transcriptional programs that distinguish SMC sublineages.

Relatively little is currently understood about the transcriptional programs and signaling pathways that regulate the specification of SMCs from undifferentiated mesenchyme during embryonic development (for a review, see references 27 and 28). The differentiation of SMCs from mesenchyme is a critical event in angiogenic patterning that ultimately distinguishes arteries, veins, and capillary beds. In the mouse, SMC markers, including SM-alpha -actin, calponin, and SM22alpha , had been detected as early as E9.5 in the dorsal aorta (27). Therefore, we were surprised to detect beta -galactosidase activity in the dorsal aorta of E8.0 unturned SM22+/-LacZ embryos. These data suggest that the signaling pathways that regulate the specification and the differentiation of vascular SMCs from the mesenchyme are activated earlier in the developing mouse embryo than was recognized previously. As such, the SM22+/-LacZ mouse and lacZ-tagged SMCs isolated from these mice may serve as valuable experimental reagents for studying the molecular basis of SMC differentiation. Moreover, because SM22alpha is downregulated in concert with other contractile proteins in atherosclerotic lesions (35-37), these mice may be used to examine the molecular mechanisms that modulate SMC phenotype and to examine the pathological mechanisms underlying vascular proliferative syndromes.

What then is the function of the cytoskeletal protein SM22alpha in SMCs and other embryonic tissues, including the developing heart and skeletal muscle? SM22alpha colocalizes with actin filaments and is abundantly expressed in contractile SMCs. It has been conserved through evolution and shows high-level sequence identity to the myofibrillar regulatory protein calponin. However, SM22alpha -deficient mice are viable and fertile and exhibit no overt phenotype. SMC-containing tissues, including arteries, veins, heart, gut, uterus, and bladder, develop normally. Basal homeostatic functions regulated in whole or in part by SMCs, including the regulation of blood pressure, bladder control, uterine contraction, and gastrointestinal motility, are not grossly altered in SM22alpha -deficient mice. Consistent with these data, the SMC ultrastructure and cytoskeletal organization in SM22alpha -deficient mice is virtually indistinguishable from their control littermates. It remains theoretically possible that SM22alpha is partially redundant with another structurally related protein such as calponin. In this regard, it is noteworthy that we recently cloned a novel mouse cDNA encoding a protein with greater than 70% sequence identity to SM22alpha that is also expressed in some SMC containing tissues (J. Zhang and M. Parmacek, unpublished data). Alternatively, SM22alpha may not be required for basal homeostatic functions but may be required for stress responses such as wound healing. The availability of SM22alpha -deficient mice allows these and other possibilities to be examined.


    ACKNOWLEDGMENTS

We thank Lisa Gottschalk for her help preparing the figures, Angie Boyce for expert secretarial assistance, and Theodore J. Plappert for technical assistance in performing echocardiography.

This project was supported in part by NIH NRSA grants HL10058 to B.P.H. and NIH-R0156915 to M.S.P. M.S.P. is an Established Investigator of the American Heart Association.


    FOOTNOTES

* Corresponding author. Mailing address: Department of Medicine, University of Pennsylvania, 91234 Founders Pavilion, 3400 Spruce St., Philadelphia, PA 19104-4283. Phone: (215) 662-3140. Fax: (215) 349-8017. E-mail: parmacek{at}mail.med.upenn.edu.


    REFERENCES
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

1. Almendral, J. M., J. F. Santaren, J. Perera, M. Zerial, and R. Bravo. 1989. Expression, cloning and cDNA sequence of a fibroblast serum-regulated gene encoding a putative actin-associated protein (p27). Exp. Cell Res. 181:518-530[CrossRef][Medline].
2. Ayme-Southgate, A., P. Lasko, C. French, and M. L. Pardue. 1989. Characterization of the gene for mp20: a Drosophila muscle protein that is not found in asynchronous oscillatory flight muscle. J. Cell Biol. 108:521-531[Abstract/Free Full Text].
3. Bradley, A. 1987. Production and analysis of chimaeric mice, p. 113-151. In E. J. Robertson (ed.), Teratocarcinomas and embryonic stem cells: a practical approach. IRL Press, Oxford, England.
4. Chan, Y. M., Q. C. Yu, J. D. Fine, and E. Fuchs. 1993. The genetic basis of Weber-Cockayne epidermolysis bullosa simplex. Proc. Natl. Acad. Sci. USA 90:7414-7418[Abstract/Free Full Text].
5. Chang, M. W., E. Barr, J. Seltzer, Y.-Q. Jiang, G. J. Nabel, E. G. Nabel, M. S. Parmacek, and J. M. Leiden. 1995. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 267:518-522[Abstract/Free Full Text].
6. Duband, J. L., M. Gimona, M. Scatena, S. Sartore, and J. V. Small. 1993. Calponin and SM22 as differentiation markers of smooth muscle: spatiotemporal distribution during avian embryonic development. Differentiation 55:1-11[CrossRef][Medline].
7. Fentzke, R. C., C. E. Korcarz, R. M. Lang, H. Lin, and J. M. Leiden. 1998. Dilated cardiomyopathy in transgenic mice expressing a dominant-negative CREB transcription factor in the heart. J. Clin. Investig. 101:2415-2426[Medline].
8. Goetinck, S., and R. H. Waterston. 1994. The Caenorhabditis elegans muscle-affecting gene unc-87 encodes a novel thin filament associated protein. J. Cell Biol. 127:79-93[Abstract/Free Full Text].
9. Helmke, B. P., R. D. Goldman, and P. F. Davies. 2000. Rapid displacement of vimentin intermediate filaments in living cells exposed to flow. Circ. Res. 86:745-752[Abstract/Free Full Text].
10. Herring, B. P., and A. F. Smith. 1996. Telokin expression is mediated by a smooth muscle cell-specific promoter. Am J. Physiol. 270:C1656-C1665[Abstract/Free Full Text].
11. Hiraoka, Y., J. W. Sedat, and D. A. Agard. 1990. Determination of three-dimensional properties of a light microscope system: partial confocal behavior in epifluorescence microscopy. Biophys. J. 57:325-333[Medline].
12. Hogan, B., R. Beddington, F. Constantini, and E. Lacy (ed.). 1994. Manipulating the mouse embryo, 2nd ed. Cold Spring Harbor Laboratory Press, Plainview, N.Y.
13. James, A. L., P. D. Pare, and J. C. Hogg. 1989. The mechanics of airway narrowing in asthma. Am. Rev. Respir. Dis. 139:242-246[Medline].
14. Kim, S., H. S. Ip, M. M. Lu, C. Clendenin, and M. S. Parmacek. 1997. A serum response factor-dependent transcriptional regulatory program identifies distinct smooth muscle cell sublineages. Mol. Cell. Biol. 17:2266-2278[Abstract].
15. Kuo, C. T., E. E. Morrisey, R. Anandappa, K. Sigrist, M. M. Lu, M. S. Parmacek, C. Soudais, and J. M. Leiden. 1997. GATA4 transcription factor is required for ventral morphogenesis and heart tube formation. Genes Dev. 11:1048-1060[Abstract/Free Full Text].
16. Lawson, D., M. Harrison, and C. Shapland. 1997. Fibroblast transgelin and smooth muscle SM22alpha are the same protein, the expression of which is down-regulated in many cell lines. Cell Motil. Cytoskel. 38:250-257[CrossRef][Medline].
17. Lees-Miller, J. P., D. H. Heeley, and L. B. Smillie. 1987. An abundant and novel protein of 22 kDa (SM22) is widely distributed in smooth muscles. Purification form bovine aorta. Biochem. J. 244:705-709[Medline].
18. Li, L., J. M. Miano, P. Cserjesi, and E. N. Olson. 1996. SM22alpha , a marker of adult smooth muscle, is expressed in multiple myogenic lineages during embryogenesis. Circ. Res. 78:188-195[Abstract/Free Full Text].
19. Li, L., J. M. Miano, B. Mercer, and E. N. Olson. 1996. Expression of the SM22alpha promoter in transgenic mice provides evidence for distinct transcriptional regulatory programs in vascular and visceral smooth muscle cells. J. Cell Biol. 132:849-859[Abstract/Free Full Text].
20. Mack, C. P., and G. K. Owens. 1999. Regulation of smooth muscle alpha -actin expression in vivo is dependent on CArG elements within the 5' and first intron promoter regions. Circ. Res. 84:852-861[Abstract/Free Full Text].
21. Madsen, C. S., R. C. P., J. E. Hungerford, S. L. White, I. Manabe, and G. K. Owens. 1998. Smooth muscle-specific expression of the smooth muscle myosin heavy chain gene in transgenic mice requires 5'-flanking and first intronic DNA sequence. Circ. Res. 82:908-917[Abstract/Free Full Text].
22. Moessler, H., M. Mericskay, Z. Li, S. Nagl, D. Paulin, and J. V. Small. 1996. The SM22 promoter directs tissue-specific expression in arterial but not in venous or visceral smooth muscle cells in transgenic mice. Development 122:2415-2425[Abstract].
23. Morrisey, E. E., H. S. Ip, Z. Tang, and M. S. Parmacek. 1997. GATA-4 activates transcription via two novel domains that are conserved within the GATA-4/5/6 subfamily. J. Biol. Chem. 272:8515-8524[Abstract/Free Full Text].
24. Morrisey, E. E., Z. Tang, K. Sigrist, M. M. Lu, F. Jiang, H. S. Ip, and M. S. Parmacek. 1998. GATA6 regulates HNF4 and is required for differentiation of visceral endoderm in the mouse embryo. Genes Dev. 12:3579-3590[Abstract/Free Full Text].
25. Newby, A. C., and A. B. Zaltsman. 1999. Fibrous cap formation or destruction---the critical importance of vascular smooth muscle cell proliferation, migration and matrix formation. Cardiovasc. Res. 41:345-360[Abstract/Free Full Text].
26. North, A. J., M. Gimona, Z. Lando, and J. V. Small. 1994. Actin isoform compartments in chicken gizzard smooth muscle cells. J. Cell. Sci. 107:445-455[Abstract].
27. Owens, G. K. 1998. Molecular control of vascular smooth muscle cell differentiation. Acta Physiol. Scand. 164:623-635[Medline].
28. Parmacek, M. S. Transcriptional programs regulating vascular smooth muscle cell development and differentiation. Curr. Top. Dev. Biol., in press.
29. Parmacek, M. S., and J. M. Leiden. 1989. Structure and expression of the murine slow/cardiac troponin C gene. J. Biol. Chem. 264:13217-13225[Abstract/Free Full Text].
30. Qian, J., A. Kumar, J. C. Szuscik, and J. L. Lessard. 1996. Tissue and developmental specific expression of murine smooth muscle gamma -actin fusion genes in transgenic mice. Dev. Dyn. 207:135-144[CrossRef][Medline].
31. Ren, W., G. Y. K. Ng, R.-X. Wang, P. H. Wu, B. F. O'Dowd, S. George, D. H. Osmond, and C. Liew. 1994. The identification of NP25: a novel protein that is differentially expressed by neuronal subpopulations. Mol. Brain Res. 22:173-185[Medline].
32. Ross, R. 1999. Mechanisms of disease: atherosclerosis---an inflammatory disease. N. Engl. J. Med. 340:115-126[Free Full Text].
33. Samaha, F. F., H. S. Ip, E. E. Morrisey, J. Seltzer, Z. Tang, J. Solway, and M. S. Parmacek. 1996. Developmental pattern of expression and genomic organization of the calponin-h1 gene; a contractile smooth muscle cell marker. J. Biol. Chem. 271:395-403[Abstract/Free Full Text].
34. Schwartz, S. M., and C. E. Murry. 1998. Proliferation and the monoclonal origins of atherosclerotic lesions. Annu. Rev. Med. 49:437-460[CrossRef][Medline].
35. Shanahan, C. M., N. R. B. Cary, J. C. Metcalfe, and P. L. Weissberg. 1994. High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J. Clin. Investig. 93:2393-2402.
36. Shanahan, C. M., and P. L. Weissberg. 1997. Smooth muscle cell heterogeneity: Patterns of gene expression in vascular smooth muscle cells in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 183:333-338.
37. Shanahan, C. M., P. L. Weissberg, and J. C. Metcalfe. 1993. Isolation of gene markers of differentiated and proliferating vascular smooth muscle cells. Circ. Res. 73:193-204[Abstract].
38. Shapland, C., J. J. Hsuan, N. F. Totty, and D. Lawson. 1993. Purification and properties of transgelin: a transformation and shape change sensitive actin-gelling protein. J. Cell Biol. 121:1065-1073[Abstract/Free Full Text].
39. Shapland, C., P. Lowings, and D. Lawson. 1988. Identification of new actin-associated polypeptides that are modified by viral transformation and changes in cell shape. J. Cell Biol. 107:153-161[Abstract/Free Full Text].
40. Small, J. V. 1985. Geometry of actin-membrane attachments in the smooth muscle cell: the localisations of vinculin and alpha -actinin. EMBO J. 4:45-49[Medline].
41. Small, J. V., and M. Gimona. 1998. The cytoskeleton of the vertebrate smooth muscle cell. Acta Physiol. Scand. 164:341-348[CrossRef][Medline].
42. Small, J. V., and A. Sobieszek. 1977. Studies on the function and composition of the 10-nm (100-A) filaments of vertebrate smooth muscle. J. Cell Sci. 23:243-268[Abstract/Free Full Text].
43. Solway, J., J. Seltzer, F. F. Samaha, S. Kim, L. E. Alger, Q. Niu, E. E. Morrisey, H. S. Ip, and M. S. Parmacek. 1995. Structure and expression of a smooth muscle cell-specific gene, SM22alpha . J. Biol. Chem. 270:13460-13469[Abstract/Free Full Text].
44. Takahashi, K., and B. Nadal-Ginard. 1991. Molecular cloning and sequence analysis of smooth muscle calponin. J. Biol. Chem. 266:13284-13288[Abstract/Free Full Text].
45. Thweatt, R., C. K. Lumpkin, and S. Goldstein. 1992. A novel gene encoding a smooth muscle protein is overexpressed in senescent human fibroblasts. Biochem. Biophys. Commun. 187:1-7[CrossRef][Medline].
46. Tybulewicz, V. L. J., C. E. Crawford, P. K. Jackson, R. T. Bronson, and R. C. Mulligan. 1991. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell 65:1153-1163[CrossRef][Medline].


Molecular and Cellular Biology, February 2001, p. 1336-1344, Vol. 21, No. 4
0270-7306/01/$04.00+0   DOI: 10.1128/MCB.2001.21.4.1336-1344.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Leguillette, R., Laviolette, M., Bergeron, C., Zitouni, N., Kogut, P., Solway, J., Kachmar, L., Hamid, Q., Lauzon, A.-M. (2009). Myosin, Transgelin, and Myosin Light Chain Kinase: Expression and Function in Asthma. Am. J. Respir. Crit. Care Med. 179: 194-204 [Abstract] [Full Text]  
  • Shi, S., Yu, L., Chiu, C., Sun, Y., Chen, J., Khitrov, G., Merkenschlager, M., Holzman, L. B., Zhang, W., Mundel, P., Bottinger, E. P. (2008). Podocyte-Selective Deletion of Dicer Induces Proteinuria and Glomerulosclerosis. J. Am. Soc. Nephrol. 19: 2159-2169 [Abstract] [Full Text]  
  • Goodwin, J. E., Zhang, J., Geller, D. S. (2008). A Critical Role for Vascular Smooth Muscle in Acute Glucocorticoid-Induced Hypertension. J. Am. Soc. Nephrol. 19: 1291-1299 [Abstract] [Full Text]  
  • Yu, H., Konigshoff, M., Jayachandran, A., Handley, D., Seeger, W., Kaminski, N., Eickelberg, O. (2008). Transgelin is a direct target of TGF-{beta}/Smad3-dependent epithelial cell migration in lung fibrosis. FASEB J. 22: 1778-1789 [Abstract] [Full Text]  
  • Wasteson, P., Johansson, B. R., Jukkola, T., Breuer, S., Akyurek, L. M., Partanen, J., Lindahl, P. (2008). Developmental origin of smooth muscle cells in the descending aorta in mice. Development 135: 1823-1832 [Abstract] [Full Text]  
  • Leguillette, R., Lauzon, A.-M. (2008). Molecular Mechanics of Smooth Muscle Contractile Proteins in Airway Hyperresponsiveness and Asthma. Proc Am Thorac Soc 5: 40-46 [Abstract] [Full Text]  
  • Carvalho, R. L. C., Itoh, F., Goumans, M.-J., Lebrin, F., Kato, M., Takahashi, S., Ema, M., Itoh, S., van Rooijen, M., Bertolino, P., ten Dijke, P., Mummery, C. L. (2007). Compensatory signalling induced in the yolk sac vasculature by deletion of TGF receptors in mice. J. Cell Sci. 120: 4269-4277 [Abstract] [Full Text]  
  • Compton, L. A., Potash, D. A., Brown, C. B., Barnett, J. V. (2007). Coronary Vessel Development Is Dependent on the Type III Transforming Growth Factor {beta} Receptor. Circ. Res. 101: 784-791 [Abstract] [Full Text]  
  • Schmidt, J. A., Avila, J. M. d., McLean, D. J. (2007). Analysis of Gene Expression in Bovine Testis Tissue Prior to Ectopic Testis Tissue Xenografting and During the Grafting Period. Biol. Reprod. 76: 1071-1080 [Abstract] [Full Text]  
  • Umans, L., Cox, L., Tjwa, M., Bito, V., Vermeire, L., Laperre, K., Sipido, K., Moons, L., Huylebroeck, D., Zwijsen, A. (2007). Inactivation of Smad5 in Endothelial Cells and Smooth Muscle Cells Demonstrates that Smad5 Is Required for Cardiac Homeostasis. Am. J. Pathol. 170: 1460-1472 [Abstract] [Full Text]  
  • Nair, R. R., Solway, J., Boyd, D. D. (2006). Expression Cloning Identifies Transgelin (SM22) as a Novel Repressor of 92-kDa Type IV Collagenase (MMP-9) Expression. J. Biol. Chem. 281: 26424-26436 [Abstract] [Full Text]  
  • Proweller, A., Tu, L., Lepore, J. J., Cheng, L., Lu, M. M., Seykora, J., Millar, S. E., Pear, W. S., Parmacek, M. S. (2006). Impaired Notch Signaling Promotes De novo Squamous Cell Carcinoma Formation.. Cancer Res. 66: 7438-7444 [Abstract] [Full Text]  
  • Balza, R. O. Jr., Misra, R. P. (2006). Role of the Serum Response Factor in Regulating Contractile Apparatus Gene Expression and Sarcomeric Integrity in Cardiomyocytes. J. Biol. Chem. 281: 6498-6510 [Abstract] [Full Text]  
  • El-Mounayri, O., Triplett, J. W., Yates, C. W., Herring, B. P. (2005). Regulation of Smooth Muscle-specific Gene Expression by Homeodomain Proteins, Hoxa10 and Hoxb8. J. Biol. Chem. 280: 25854-25863 [Abstract] [Full Text]  
  • Owens, G. K., Kumar, M. S., Wamhoff, B. R. (2004). Molecular Regulation of Vascular Smooth Muscle Cell Differentiation in Development and Disease. Physiol. Rev. 84: 767-801 [Abstract] [Full Text]  
  • Feil, S., Hofmann, F., Feil, R. (2004). SM22{alpha} Modulates Vascular Smooth Muscle Cell Phenotype During Atherogenesis. Circ. Res. 94: 863-865 [Abstract] [Full Text]  
  • Kaplan-Albuquerque, N., Garat, C., Van Putten, V., Nemenoff, R. A. (2003). Regulation of SM22{alpha} expression by arginine vasopressin and PDGF-BB in vascular smooth muscle cells. Am. J. Physiol. Heart Circ. Physiol. 285: H1444-H1452 [Abstract] [Full Text]  
  • Du, K. L., Ip, H. S., Li, J., Chen, M., Dandre, F., Yu, W., Lu, M. M., Owens, G. K., Parmacek, M. S. (2003). Myocardin Is a Critical Serum Response Factor Cofactor in the Transcriptional Program Regulating Smooth Muscle Cell Differentiation. Mol. Cell. Biol. 23: 2425-2437 [Abstract] [Full Text]  
  • Xu, R., Ho, Y.-S., Ritchie, R. P., Li, L. (2003). Human SM22alpha BAC encompasses regulatory sequences for expression in vascular and visceral smooth muscles at fetal and adult stages. Am. J. Physiol. Heart Circ. Physiol. 284: H1398-H1407 [Abstract] [Full Text]  
  • Shu, W., Jiang, Y. Q., Lu, M. M., Morrisey, E. E. (2003). Wnt7b regulates mesenchymal proliferation and vascular development in the lung. Development 129: 4831-4842 [Abstract] [Full Text]  
  • Li, W. E. I., Waldo, K., Linask, K. L., Chen, T., Wessels, A., Parmacek, M. S., Kirby, M. L., Lo, C. W. (2003). An essential role for connexin43 gap junctions in mouse coronary artery development. Development 129: 2031-2042 [Abstract] [Full Text]  
  • Chen, S., Kulik, M., Lechleider, R. J. (2003). Smad proteins regulate transcriptional induction of the SM22{alpha} gene by TGF-{beta}. Nucleic Acids Res 31: 1302-1310 [Abstract] [Full Text]  
  • Wulfkuhle, J. D., Sgroi, D. C., Krutzsch, H., McLean, K., McGarvey, K., Knowlton, M., Chen, S., Shu, H., Sahin, A., Kurek, R., Wallwiener, D., Merino, M. J., Petricoin, E. F. III, Zhao, Y., Steeg, P. S. (2002). Proteomics of Human Breast Ductal Carcinoma in Situ. Cancer Res. 62: 6740-6749 [Abstract] [Full Text]  
  • Desjardins, P. R., Burkman, J. M., Shrager, J. B., Allmond, L. A., Stedman, H. H. (2002). Evolutionary Implications of Three Novel Members of the Human Sarcomeric Myosin Heavy Chain Gene Family. Mol Biol Evol 19: 375-393 [Abstract] [Full Text]  
  • Morgan, K. G., Gangopadhyay, S. S. (2001). Signal Transduction in Smooth Muscle: Invited Review: Cross-bridge regulation by thin filament-associated proteins. J. Appl. Physiol. 91: 953-962 [Abstract] [Full Text]  
  • Strobeck, M., Kim, S., Zhang, J. C. L., Clendenin, C., Du, K. L., Parmacek, M. S. (2001). Binding of Serum Response Factor to CArG Box Sequences Is Necessary but Not Sufficient to Restrict Gene Expression to Arterial Smooth Muscle Cells. J. Biol. Chem. 276: 16418-16424 [Abstract] [Full Text]  
  • Steitz, S. A., Speer, M. Y., Curinga, G., Yang, H.-Y., Haynes, P., Aebersold, R., Schinke, T., Karsenty, G., Giachelli, C. M. (2001). Smooth Muscle Cell Phenotypic Transition Associated With Calcification: Upregulation of Cbfa1 and Downregulation of Smooth Muscle Lineage Markers. Circ. Res. 89: 1147-1154 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, J. C. L.
Right arrow Articles by Parmacek, M. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, J. C. L.
Right arrow Articles by Parmacek, M. S.